Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Chemotherapy in First-line Soft Tissue Sarcoma
NCT04356872Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Mar 2022
- Countries
- 1
- Sponsor
- Fudan University
- Modality
- Monoclonal Antibodies
- Drugs
- sintilimab
- Conditions
- soft tissue sarcoma (STS)
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in soft tissue sarcoma (STS), sponsored by Fudan University. Primary endpoint: Overall Response Rate up to 2 years. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Experimental Arm
Sintilimab + Doxorubicin + Ifosfamide followed by Sintilimab maintenance
03
Endpoints
Primary
Overall Response Rate
Secondary
Progression Free Survival
Adverse Events
Overall Survival
Beyond the preview
Go deeper on NCT04356872.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356872.